TLR4 and breast carcinoma: Our work provides new insight into the development/progression of inflammation and breast cancer, suggesting that activation of the TLR4-MyD88 signaling pathway or MyD88 alone may be risk factors for a poor breast cancer prognosis and may be novel targets for the development of biomodulators.